Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 19/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 19/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 19/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28781360 | 0.94 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3TP53CYP3A4 | |
| SCHEMBL872717 | 0.92 | SLC6A2 (0.80) | SLC6A2SLC6A4SLC6A3TP53CYP3A4 | |
| SCHEMBL872721 | 0.90 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL872240 | 0.89 | SLC6A4 (0.85) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL871604 | 0.87 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3TP53CYP3A4 | |
| SCHEMBL12235313 | 0.85 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3TP53CYP3A4 | |
| SCHEMBL15422780 | 0.82 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3TP53CYP3A4 | |
| SCHEMBL872352 | 0.81 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2270926 | 0.81 | SLC6A4 (0.61) | SLC6A2SLC6A4SLC6A3TP53CYP3A4 | |
| SCHEMBL15499907 | 0.81 | SLC6A2 (0.77) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296681-B2 | Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9096515-B2 | Methods of using cycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140066500-A1 | CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140024709-A1 | METHODS OF USING CYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8604244-B2 | Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20120172426-A1 | Compositions, Synthesis, and Methods of Using Cycloalkylmethylamine Derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2012003501-A2 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING CYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066500-A1 | CYCLOALKYLMETHYLAMINES | PNMT, TPH1, TPH2 | SLC6A2 77/4885SLC6A4 15/4885SLC6A3 60/4885 |
| US-20120172426-A1 | Compositions, Synthesis, and Methods of Using Cycloalkylmethylamine Derivatives | TPH1, TPH2, PNMT | SLC6A2 192/4885SLC6A4 33/4885SLC6A3 119/4885 |
| US-20140024709-A1 | METHODS OF USING CYCLOALKYLMETHYLAMINE DERIVATIVES | PNMT, TPH1, TPH2 | SLC6A2 97/4885SLC6A4 20/4885SLC6A3 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.